medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2015, Número 5

<< Anterior Siguiente >>

Acta Pediatr Mex 2015; 36 (5)


Linfoma no Hodgkin primario de sistema nervioso central en un paciente pediátrico sin inmunodeficiencia relacionada

Cárdenas-Cardos R, Aguilar-Ortiz MR, Velasco-Hidalgo L, Pasquel García-Vázquez PM, Rivera-Luna R, Marhx-Bracho A

Idioma: Español
Referencias bibliográficas: 25
Paginas: 389-396
Archivo PDF: 884.48 Kb.


RESUMEN

El linfoma no Hodgkin primario de sistema nervioso central es una afección poco frecuente en la población pediátrica. No existen (o son pocas) las recomendaciones o estudios clínicos que sean útiles para definir la mejor opción terapéutica. El objetivo de este trabajo es describir el caso de una niña con linfoma primario de sistema nervioso central, sin ninguna inmunodeficiencia asociada, y realizar de una revisión cualitativa de la literatura especializada sobre esta enfermedad en niños.
Se ha postulado la posibilidad de cambios citogenéticos que pudieran explicar la heterogeneidad en el comportamiento de esta enfermedad pues se ha visto que es distinto al de otros linfomas en presentaciones habituales. La experiencia de tratamiento en niños con linfoma se basa en resultados de tratamientos obtenidos en pacientes adultos, con regímenes basados principalmente en antimetabolitos como metotrexato y citarabina. Aún es controvertida la utilidad de la radioterapia craneal, la cual sólo se recomienda en casos específicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lois D, Ohgaki H, Wiestler O. WHO classification of tumors of the central nervous system. Lyon, France: IARC 2007:189-192.

  2. Batchelor T, Loeffler JS. Primary CNS Lymphoma. J Clin Oncol 2006;24:1281-1288.

  3. Padhi S, Roshni TP, Challa S. Primary extranodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pacific J Cancer Prev 2012;13:4889-4895.

  4. Abla O, Weitzman S, Blay JY, O’Neill BP, Abrey LE, Neuwelt E, et al. Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res 2011;17(2):346-352.

  5. O Abla, Sandlund JT, Sung L, Brock P, Corbett R, Kirov I, et al. A Case Series of Pediatric Primary Central Nervous System Lymphoma: Favorable Outcome Without Cranial Irradiation. Pediatr Blood Cancer 2006;47:880–885.

  6. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J Clin Oncol 2006;24:5711-5715.

  7. Esptein LG, Frederick J, Dicarlo J, et al. Primary lymphoma of the central nervous system in children with acquired immunodeficiency syndrome. Pediatrics 1988;82:355-363.

  8. Jiménez VH, Domínguez V, López-Karpovitch X. Linfoma primario del sistema nervioso central: epidemiología, biología, diagnóstico y tratamiento. Med Int Mex 2007;23:66-77.

  9. Atra A, Imeson JD, Hobson R, Gerrard M, Hann IM, Eden OB, et al. Improved Outcome in children with advanced stage B-Cell non-Hodgkin’s lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000;82:1396-1402.

  10. Patte C, Auperin A, Michon J, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.

  11. Ferreri A, Abrey L, Blay J, Borisch B, Hochman J, Neuwelt E, et al. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002 J Clin Oncol 2003;2:2407-2414.

  12. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, et al. Prevalence, Clinical Pattern, and Outcome of CNS Involvement in Childhood and Adolescent Non-Hodgkin’s Lymphoma Differ by Non-Hodgkin’s Lymphoma Subtype: A Berlin-Frankfurt-Münster Group Report. J Clin Oncol 2007;25:3915-3922.

  13. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339.

  14. Reiter A, Schrappe M, Parwaresch R, Henze G, Müller- Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol 1995;13:359-72.

  15. Hyung JY, Jin HK, Kim H, et al. Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience. J Korean Med Sci 2012;27:1378-84.

  16. Pels H, Schmidt-Wolf IGH, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy. J Clin Oncol 2003;21:4489-4495.

  17. Angelov L, Doolittle ND, Kraemer DF, Siegal T, Barnett GH, Peereboom DM, et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience. J Clin Oncol 2009;27:3503-3509.

  18. Campen CJ, Tombleson RL, Green MR. High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma. J Neurooncol 2011;101:345–355.

  19. Makino K, Nakamura H, Yano S, Kuratsu JI. Pediatric primary CNS lymphoma: longterm survival after treatment with radiation monotherapy. Acta Neurochir (Wien) 2007;149:295–298.

  20. Escamilla AG, Cárdenas CR, et al. Linfoma no Hodgkin B. en: Rivera-Luna R editor. Protocolos Técnicos Cáncer en Niños, Consejo Nacional para la Prevención y el Tratamiento del Cáncer en la Infancia y la Adolescencia, 1ª ed. México, Editores de Textos Mexicanos S.A. de C.V. 2010, pp. 102-117.

  21. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton C, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-2743.

  22. Omuro A, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007;85:207–211.

  23. Voloschin A, Betensky R, Y. Wen P, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008;86:211–215.

  24. Cady FM, O’Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, et al. Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course. J Clin Oncol 2008;26:4814-4819.

  25. Ferreri AJM, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. J Clin Oncol 2003;21:266-272.




2020     |     www.medigraphic.com